Costs associated with symptomatic systolic heart failure

Peter G. Davey (Lead / Corresponding author), Peter B.M. Clarkson, Alex McMahon, Thomas M. MacDonald

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To investigate whether the extent of systolic dysfunction is a useful predictor of the costs of healthcare and social support for patients With heart failure. Design: Cross-sectional study with collection of cost data attributed to management of heart failure in the previous year. Setting: Four primary-care practices in Scotland. Patients: Patients receiving long term therapy with loop diuretics for suspected heart failure. Interventions: Two-dimensional and Doppler echocardiography. Main outcome measures and results: Two hypotheses were tested: (i) the proportion of patients incurring costs is higher in patients with abnormal left ventricular (LV) function; and (ii) the median cost per patient that incurs costs is higher in patients with abnormal LV function. Of the 226 patients in the study, 67 (30%) had abnormal systolic function. In comparison with the remaining 159 patients, they had higher healthcare costs [£560 vs £440 per patient year (1994/1995 values)], were more likely to incur hospital inpatient or outpatient costs [Odds ratio (OR): 2.02; 95% confidence interval (CI): 1.06 to 3.84] and had significantly higher primary-care costs (mean £292 vs £231 per patient year; p = 0.02, Mann Whitney test). In contrast, they were no more likely to incur social support costs (OR: 1.22; 95% CI: 0.52 to 2.86) and the mean cost of social support per patient year was lower (£234 vs £373). Conclusions: Patients with objectively measured systolic dysfunction incurred significantly higher healthcare costs in the year before diagnosis. This suggests that treatment that improves systolic function will reduce healthcare costs, even in a primary-care population with relatively mild congestive heart failure.

Original languageEnglish
Pages (from-to)399-407
Number of pages9
JournalPharmacoEconomics
Volume16
Issue number4
DOIs
Publication statusPublished - 3 Nov 1999

Fingerprint

Systolic Heart Failure
Costs and Cost Analysis
Health Care Costs
Heart Failure
Social Support
Primary Health Care
Left Ventricular Function
Odds Ratio
Confidence Intervals
Sodium Potassium Chloride Symporter Inhibitors
Doppler Echocardiography
Scotland

Cite this

Davey, Peter G. ; Clarkson, Peter B.M. ; McMahon, Alex ; MacDonald, Thomas M. / Costs associated with symptomatic systolic heart failure. In: PharmacoEconomics. 1999 ; Vol. 16, No. 4. pp. 399-407.
@article{915b9907883e44339f38b0088c56d2c3,
title = "Costs associated with symptomatic systolic heart failure",
abstract = "Objective: To investigate whether the extent of systolic dysfunction is a useful predictor of the costs of healthcare and social support for patients With heart failure. Design: Cross-sectional study with collection of cost data attributed to management of heart failure in the previous year. Setting: Four primary-care practices in Scotland. Patients: Patients receiving long term therapy with loop diuretics for suspected heart failure. Interventions: Two-dimensional and Doppler echocardiography. Main outcome measures and results: Two hypotheses were tested: (i) the proportion of patients incurring costs is higher in patients with abnormal left ventricular (LV) function; and (ii) the median cost per patient that incurs costs is higher in patients with abnormal LV function. Of the 226 patients in the study, 67 (30{\%}) had abnormal systolic function. In comparison with the remaining 159 patients, they had higher healthcare costs [£560 vs £440 per patient year (1994/1995 values)], were more likely to incur hospital inpatient or outpatient costs [Odds ratio (OR): 2.02; 95{\%} confidence interval (CI): 1.06 to 3.84] and had significantly higher primary-care costs (mean £292 vs £231 per patient year; p = 0.02, Mann Whitney test). In contrast, they were no more likely to incur social support costs (OR: 1.22; 95{\%} CI: 0.52 to 2.86) and the mean cost of social support per patient year was lower (£234 vs £373). Conclusions: Patients with objectively measured systolic dysfunction incurred significantly higher healthcare costs in the year before diagnosis. This suggests that treatment that improves systolic function will reduce healthcare costs, even in a primary-care population with relatively mild congestive heart failure.",
author = "Davey, {Peter G.} and Clarkson, {Peter B.M.} and Alex McMahon and MacDonald, {Thomas M.}",
year = "1999",
month = "11",
day = "3",
doi = "10.2165/00019053-199916040-00007",
language = "English",
volume = "16",
pages = "399--407",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Springer Verlag",
number = "4",

}

Costs associated with symptomatic systolic heart failure. / Davey, Peter G. (Lead / Corresponding author); Clarkson, Peter B.M.; McMahon, Alex; MacDonald, Thomas M.

In: PharmacoEconomics, Vol. 16, No. 4, 03.11.1999, p. 399-407.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Costs associated with symptomatic systolic heart failure

AU - Davey, Peter G.

AU - Clarkson, Peter B.M.

AU - McMahon, Alex

AU - MacDonald, Thomas M.

PY - 1999/11/3

Y1 - 1999/11/3

N2 - Objective: To investigate whether the extent of systolic dysfunction is a useful predictor of the costs of healthcare and social support for patients With heart failure. Design: Cross-sectional study with collection of cost data attributed to management of heart failure in the previous year. Setting: Four primary-care practices in Scotland. Patients: Patients receiving long term therapy with loop diuretics for suspected heart failure. Interventions: Two-dimensional and Doppler echocardiography. Main outcome measures and results: Two hypotheses were tested: (i) the proportion of patients incurring costs is higher in patients with abnormal left ventricular (LV) function; and (ii) the median cost per patient that incurs costs is higher in patients with abnormal LV function. Of the 226 patients in the study, 67 (30%) had abnormal systolic function. In comparison with the remaining 159 patients, they had higher healthcare costs [£560 vs £440 per patient year (1994/1995 values)], were more likely to incur hospital inpatient or outpatient costs [Odds ratio (OR): 2.02; 95% confidence interval (CI): 1.06 to 3.84] and had significantly higher primary-care costs (mean £292 vs £231 per patient year; p = 0.02, Mann Whitney test). In contrast, they were no more likely to incur social support costs (OR: 1.22; 95% CI: 0.52 to 2.86) and the mean cost of social support per patient year was lower (£234 vs £373). Conclusions: Patients with objectively measured systolic dysfunction incurred significantly higher healthcare costs in the year before diagnosis. This suggests that treatment that improves systolic function will reduce healthcare costs, even in a primary-care population with relatively mild congestive heart failure.

AB - Objective: To investigate whether the extent of systolic dysfunction is a useful predictor of the costs of healthcare and social support for patients With heart failure. Design: Cross-sectional study with collection of cost data attributed to management of heart failure in the previous year. Setting: Four primary-care practices in Scotland. Patients: Patients receiving long term therapy with loop diuretics for suspected heart failure. Interventions: Two-dimensional and Doppler echocardiography. Main outcome measures and results: Two hypotheses were tested: (i) the proportion of patients incurring costs is higher in patients with abnormal left ventricular (LV) function; and (ii) the median cost per patient that incurs costs is higher in patients with abnormal LV function. Of the 226 patients in the study, 67 (30%) had abnormal systolic function. In comparison with the remaining 159 patients, they had higher healthcare costs [£560 vs £440 per patient year (1994/1995 values)], were more likely to incur hospital inpatient or outpatient costs [Odds ratio (OR): 2.02; 95% confidence interval (CI): 1.06 to 3.84] and had significantly higher primary-care costs (mean £292 vs £231 per patient year; p = 0.02, Mann Whitney test). In contrast, they were no more likely to incur social support costs (OR: 1.22; 95% CI: 0.52 to 2.86) and the mean cost of social support per patient year was lower (£234 vs £373). Conclusions: Patients with objectively measured systolic dysfunction incurred significantly higher healthcare costs in the year before diagnosis. This suggests that treatment that improves systolic function will reduce healthcare costs, even in a primary-care population with relatively mild congestive heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0032727954&partnerID=8YFLogxK

U2 - 10.2165/00019053-199916040-00007

DO - 10.2165/00019053-199916040-00007

M3 - Article

VL - 16

SP - 399

EP - 407

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 4

ER -